Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM: Romiplostim for Chemotherapy-induced Thrombocytopenia in Solid Tumors
NCT03937154Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2020
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Amgen. Started Feb 2020; status: active, not recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT03937154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937154.